Skip to content
ASCO logo

ASCO

85 interviews

American Society of Clinical Oncology Annual Meeting

Interviews and expert commentary from ASCO — study authors and key opinion leaders discuss the findings and their clinical implications.

Official website ↗
John Mascarenhas MD; ASCO 2026: New Janus Kinase Inhibitor Improves Myelofibrosis Outcomes When Added to Ruxolitinib Initial Therapy

John Mascarenhas MD; ASCO 2026: New Janus Kinase Inhibitor Improves Myelofibrosis Outcomes When Added to Ruxolitinib Initial Therapy

CHICAGO, USA—Outcomes were improved for patients with myelofibrosis in the phase 3 SENTRY trial who were randomized to have the new Janus kinase inhibitor selinexor added to their ruxolitinib initial…

31 August 2026
13 min
David R Spigel MD; ASCO 2026: EGFR Exon-20 Insertion Directed Initial Therapy Cuts Disease Progression in Patients with Advanced Non-Small Cell Lung Cancer

David R Spigel MD; ASCO 2026: EGFR Exon-20 Insertion Directed Initial Therapy Cuts Disease Progression in Patients with Advanced Non-Small Cell Lung Cancer

CHICAGO, USA—For patients with advanced non-small cell lung cancer harboring the rare exon-20 gene insertion,first-line treatment with the targeted drug sunvozertinib monotherapy brought…

25 August 2026
4 min
Jefferson DeKloe BSc: Big US Study Confirms Benefit of HPV Vaccination for Boys as Well as Girls

Jefferson DeKloe BSc: Big US Study Confirms Benefit of HPV Vaccination for Boys as Well as Girls

The cancer prevention benefit of vaccination against the human papilloma virus cancer prevent are slowly accruing thanks to European, American and other population-based studies.  I’m Peter Goodwin wi

1 October 2025
6 min
Rebecca Dent MD: First-Line T-DXd Combination Adds More Than a Year of Progression Free Survival for Patients with Advanced HER2 Positive Breast Cancer

Rebecca Dent MD: First-Line T-DXd Combination Adds More Than a Year of Progression Free Survival for Patients with Advanced HER2 Positive Breast Cancer

Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+

25 July 2025
Erica L. Mayer MD MPH: Adjuvant Abemaciclib: Start Low, then Dose Escalate in Early-stage HR+/HER2- Breast Cancer: TRADE Study Findings

Erica L. Mayer MD MPH: Adjuvant Abemaciclib: Start Low, then Dose Escalate in Early-stage HR+/HER2- Breast Cancer: TRADE Study Findings

Interview with Erica L. Mayer MD MPH, Director of Breast Cancer Clinical Research, Breast Oncology Program, Dana-Farber Cancer Institute, Boston, USA. With comment from: Pat Price MD, Imperial College

18 July 2025
9 min
Patients with Early-Stage Non-Squamous Non-Small Cell Lung Cancer Who can Benefit from Adjuvant Chemotherapy

Patients with Early-Stage Non-Squamous Non-Small Cell Lung Cancer Who can Benefit from Adjuvant Chemotherapy

An interview with: David R Spigel FASCO, MD, Chief Scientific Officer, Sarah Cannon Research Institute, Nashville, Tennessee, US With comment from: Luis G Paz-Ares MD PhD Chair of Medical Oncology, Ho

12 July 2025
12 min
Adjuvant Nivolumab Extends Disease-Free Survival in Patients with High-Risk Head and Neck Cancers

Adjuvant Nivolumab Extends Disease-Free Survival in Patients with High-Risk Head and Neck Cancers

“Adjuvant nivolumab added to chemoradiotherapy after surgery provided a statistically and clinically meaningful disease-free survival improvement in PD-L1 all-comers patients. This is the first time i

3 July 2025
10 min
Elena Elez, Barcelona, ASCO: BRAF Inhibitor Encorafenib Delays Progression, Extends Survival in Patients with Inoperable BRAF V600E Mutant Colorectal Cancer

Elena Elez, Barcelona, ASCO: BRAF Inhibitor Encorafenib Delays Progression, Extends Survival in Patients with Inoperable BRAF V600E Mutant Colorectal Cancer

An interview with: Elena Elez MD PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain CHICAGO, USA—Adding the BRAF inhibitor encorafenib (partnered with EGFR-inhibitor cetuximab) to standa

19 June 2025
16 min
Yelena Janjigian ASCO Plenary: Peri-Operative Chemo-Immunotherapy Delays Recurrence in Patients with Gastric or GE Junction Cancers

Yelena Janjigian ASCO Plenary: Peri-Operative Chemo-Immunotherapy Delays Recurrence in Patients with Gastric or GE Junction Cancers

Yelena Y. Janjigian MD says that perioperative anti-PD-L1 immunotherapy with durvalumab was a “game changer” meriting use as a new standard of care when used together with chemotherapy to

17 June 2025
5 min
Christopher Booth MD: Post-Surgery Exercise Therapy Reduced Recurrence Risk and Extended Life in Patients with Colon Cancer

Christopher Booth MD: Post-Surgery Exercise Therapy Reduced Recurrence Risk and Extended Life in Patients with Colon Cancer

Exercise was as good as the addition of a drug among patients with high risk stage 2 or stage 3 colon cancer after curative surgery, extending life and preventing cancer recurrence. Christopher Booth

12 June 2025
11 min
Frank A Sinicrope MD: Stage 3 Colon Cancer with Deficient Mismatch Repair: Big Gains from Atezolizumab Added to Standard Chemotherapy

Frank A Sinicrope MD: Stage 3 Colon Cancer with Deficient Mismatch Repair: Big Gains from Atezolizumab Added to Standard Chemotherapy

An interview with: Frank A Sinicrope, MD, Medical Oncologist, Mayo Clinic, Rochester, Minnesota. CHICAGO —Big gains in survival have been reported among patients with stage three, node-positive colon

10 June 2025
7 min